Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 03, 2022

SELL
$1.12 - $1.61 $450,352 - $647,381
-402,100 Closed
0 $0
Q1 2022

Apr 28, 2022

BUY
$1.21 - $2.48 $44,286 - $90,768
36,600 Added 10.01%
402,100 $607,000
Q4 2021

Feb 02, 2022

SELL
$1.84 - $2.68 $339,480 - $494,460
-184,500 Reduced 33.55%
365,500 $887,000
Q2 2021

Aug 05, 2021

BUY
$2.17 - $3.0 $1.19 Million - $1.65 Million
550,000 New
550,000 $1.59 Million

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $93.4M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.